Sep 072013
 

8384889861_d445f4dfa1_m

St George’s, University of London research has found that a drug normally given to osteoporosis sufferers could provide effective pain relief to patients with knee and hip osteoarthritis.

Bisphosphonates are a group of drugs known to change the structure of bone and are most often prescribed to patients with osteoporosis, a condition characterised by fragile bones.

It is unknown, however, whether these drugs could be used to reduce pain and discomfort for patients with the joint condition osteoarthritis, which causes cartilage damage, bony growths and sore tissue.

The researchers used existing studies to assess the effectiveness of a variety of bisphosphonates in patients suffering from osteoarthritis of the hand, knee, spine and hips.

Of 3832 patients studied, in most cases these drugs showed limited pain relief. However, a few studies did show benefit; the bisphosphonate alendronate was found to be more effective for patients with hip osteoarthritis than existing pain relieving drugs. Moreover, the use of zoledronate and alendronate, specific forms of bisphosphonates, improved pain in patients with knee and hip osteoarthritis at six months —but longer term studies are needed.

Dr Nidhi Sofat, lead researcher, said: “Osteoarthritis is the most common form of arthritis worldwide. It causes damage to bone and cartilage in the joints of affected people. Most treatment is focused around pain relief, as no robust treatments have been discovered that slow down the progression of the disease.

“Our study looked at whether there were any bisphosphonate drugs that have been shown to influence pain and/or disease progression that could be used in osteoarthritis treatment.

“We found that, generally, bisphosphonates are ineffective at managing pain associated with osteoarthritis. But zoledronate and alendronate, which are specific forms of bisphosphonates, do show the potential for effective pain management specifically in patients with knee and hip osteoarthritis.

Read more . . .

 

The Latest on: Bisphosphonates
  • Amgen (AMGN) Says New Data to be Presented at ASH 2017 Underscore its Commitment to Patients With Difficult-To-Treat Blood Cancers
    on December 7, 2017 at 6:27 am

    Of note, a study evaluating patterns and predictors of initiation of intravenous bisphosphonates among multiple myeloma patients will be highlighted in an oral session. In the study, less than half of patients initiated bisphosphonate treatment in the two ... […]

  • Bisphosphonates in Early Breast Cancer: 2 Years vs 5 Years
    on December 6, 2017 at 12:00 am

    A study found no difference in outcomes between 2 and 5 years of treatment with zoledronate after chemotherapy in early breast cancer patients, suggesting the longer duration may not be necessary. “Bisphosphonates prevent the loss of bone density and ... […]

  • How to keep your bones strong
    on December 5, 2017 at 2:01 pm

    Common drugs used for this purpose include bisphosphonates, such as alendronate (Fosamax), ibandronate (Boniva) and risedronate (Actonel); denosumab (Prolia, Xgeva); raloxifene (Evista); and calcitonin (Calcitonin-Salmon, Fortical, Miacalcin). […]

  • What We Know (and Don't Know) About Bisphosphonates
    on February 11, 2017 at 4:00 pm

    Veterinarians can administer bisphosphonates either IV or IM. Once in the body, the drug binds to bone mineral, particularly at sites of active bone resorption. In 2014, the U.S Food and Drug Administration (FDA) approved the use of the bisphosphonates ... […]

  • New Cautions About Long-Term Use of Bone Drugs
    on May 8, 2012 at 5:00 pm

    The F.D.A. review, published in The New England Journal of Medicine online on Wednesday, was prompted by a growing debate over how long women should continue using the drugs, known as bisphosphonates, which are sold as generic versions of brands like ... […]

  • Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm
    on January 23, 2009 at 4:00 pm

    A method of placing patients into a risk category for bisphosphonate osteonecrosis of the jaws following a tooth extraction is proposed. This information can be used in the informed consent process prior to a planned tooth extraction. A management protocol ... […]

  • Bisphosphonates Cause Rare Eye Inflammation
    on September 23, 2008 at 5:00 pm

    WEDNESDAY, Sept. 24 (HealthDay News) -- Doctors can now add inflammatory eye disease to the list of potential side effects from the bone medications known as bisphosphonates. Though exceedingly rare -- only four cases have been reported in the medical ... […]

via Google News and Bing News

Other Interesting Posts

Leave a Reply

%d bloggers like this: